Trends in C-Level Salaries and Benefits in the Biotech Market
Skills at Biotech’s C-suite level have evolved: has compensation?
The new 2013 Executive Compensation Report delivers systematic compensation data on 798 C-Level executives representing 258 companies. This year, the scope has gone international for the first time! The 2013 Executive Compensation Report includes 25% more companies including the addition of 87 executives representing 55 non-U.S. companies.
The biopharma market is quite unpredictable these days with downsizings, failing companies, M&As and pharmas recruiting biotech executives to jumpstart their R&D agendas. The 2013 Executive Compensation Report monitors, evaluates and formulates trends in the executive compensation paradigms and activities in the biotech market. The new Executive Compensation Report enables you to negotiate from a position of strength and knowledge. It allows you to determine your rank among peers, make competent hiring offers, facilitate the annual executive review process or keep abreast of the market salary dynamics and more!
The BioWorld Executive Compensation Report 2013 provides you with complete salary, bonus and market capitalization data and rankings of six top-level job titles:
- Chief Executive Officers
- Chief Financial Officers
- Chief Operating Officers
- VPs of Research and Development
- Chief Legal Officers
- Heads of Business/Corporate Development
Biotechnology is the fastest- growing sector in the life sciences market and that stimulates hiring in C-Level positions to manage growth - Be armed and prepared!
Executive Compensation Report 2013
Only $399.00, plus $19.99 shipping & handling
Print & PDF version with interactive point & click features – only $399.00, plus $19.99 shipping & handling